Brandon Smith, NP
Nurse Practitioner · Chubbuck, IDNPI 1255947255
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 33.9% of the total. Among nurse practitioner clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 144 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$891
- Lilly USA, LLC$299
- Novo Nordisk$293
- Amgen$203
- Astellas Pharma US Inc$168
- Sanofi Pasteur Inc.$92
- plus $681 from 19 others
What the payments were for
- Speaking & faculty fees$341%
- Food & beverage$2,59499%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $891 |
| Lilly USA, LLC | 21 | $299 |
| Novo Nordisk | 17 | $293 |
| Amgen | 12 | $203 |
| Astellas Pharma US Inc | 7 | $168 |
| Sanofi Pasteur Inc. | 4 | $92 |
| Exact Sciences | 4 | $79 |
| Johnson & Johnson | 3 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $57 |
| AstraZeneca | 4 | $55 |
| Pfizer | 3 | $50 |
| Boehringer Ingelheim | 3 | $43 |
| Phathom Pharmaceuticals, Inc. | 3 | $41 |
| Viatris Specialty LLC | 2 | $39 |
| BD | 1 | $34 |
| Boston Scientific | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Tandem Diabetes Care, Inc. | 2 | $26 |
| GSK | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Tris Pharma Inc | 1 | $20 |
| Medtronic | 1 | $18 |
| Corcept Therapeutics | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $14 |
How this compares
$2,628 in reported general payments places this provider in the 90th percentile of 570 nurse practitioner providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $49,789 |
| JardianceEmpagliflozin | 17 | $15,934 |
| EliquisApixaban | 19 | $15,620 |
| FarxigaDapagliflozin Propanediol | 13 | $14,611 |
| MounjaroTirzepatide | 14 | $14,335 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,996 |
| Pregabalin | 32 | $3,164 |
| Celecoxib | 20 | $2,816 |
| Duloxetine Hcl | 59 | $1,792 |
| Levothyroxine Sodium | 138 | $1,340 |
| Gabapentin | 62 | $1,060 |
| Omeprazole | 95 | $1,034 |
| Trazodone Hcl | 52 | $807 |
| Atorvastatin Calcium | 87 | $770 |
| Oxybutynin Chloride ErOxybutynin Chloride | 25 | $743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $293 | $49,78948 claims |
| Boehringer IngelheimJardiance | $43 | $15,93417 claims |
| PfizerEliquis | $50 | $15,62019 claims |
| AstraZenecaFarxiga | $55 | $14,61113 claims |
| Lilly USA, LLCMounjaro | $299 | $14,33514 claims |
| GSKTrelegy Ellipta | $25 | $7,99612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 570 nurse practitioner providers in Idaho.
Other nurse practitioner in Chubbuck
- Hyrum DavenportChubbuck$8K
- Kathleen CliffordBoise$119K
- Alissa HelvikCoeur D Alene$93K
- Amanda ThompsonIdaho Falls$67K
- Micalena PerkinsBurley$44K
- Tosha JohnsonNampa$26K
- Loreen NugentBoise$20K
- Rachel RyanMeridian$19K
- Stephanie HartPost Falls$18K
- Joshua ScovilleTwin Falls$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.